Composition for treating brain lesions

A composition and polymer technology, applied in the direction of drug combination, medical raw materials derived from mammals, drug delivery, etc., can solve the problems of restricting the introduction of grafts

Inactive Publication Date: 2018-03-30
生物组织再生和修复公司 +3
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This phenomenon is concurrent with the presence of free

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for treating brain lesions
  • Composition for treating brain lesions
  • Composition for treating brain lesions

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0133] Example 1: Evaluation of the effect of biocompatible polymers according to the invention on brain damage and functional deficits caused by cerebral ischemia

[0134] In this example, the biocompatible polymer is the polymer sold by the company OTR3 under the trade number OTR 4131, which is described in Frescaline G. et al., Tissue Eng Part A. 2013 Jul; 19(13-14): 1641-53.doi:10.1089 / ten.TEA.2012.0377 and is commercially available.

[0135] Rats were Sprague Dawley strain male rats.

[0136] To define the effect of OTR 4131 biocompatible polymer on brain damage and functional deficits, in rats with transient cerebral ischemia caused by occluded middle cerebral artery figure 1 Experimental protocol shown.

[0137] Specifically, by inhaling O 2 / N 2Animals were anesthetized with 5% isoflurane in O mixture (1 / 3 ratio each) for 3 min and then maintained by mask delivery of 2-2.5% isoflurane during surgery. Lay the rat on its back. The incision is made at the level of t...

Embodiment 2

[0145] Example 2: Evaluation of the effects of co-administration of biocompatible polymers and mesenchymal stem cells on brain damage and functional deficits caused by ischemic shock

[0146] In this example, rats and biocompatible polymers were the same as those in Example 1.

[0147] According to the method described in the document Quittet et al., "Effects of mesenchymal stem cell therapy, inassociation with pharmacologically active microcarriers releasing VEGF, in anischaemic stroke model in the rat" Acta Biomater. 2015 Mar; 15:77-88, by Sprague Dawley Mesenchymal stem cells were extracted from rat femur and tibia.

[0148] In order to define the effect of co-administration of OTR 4131 biocompatible polymer and mesenchymal stem cells on brain damage and functional deficits, following the intraluminal method as described in Example 1 above, in transient in ischemic rats Figure 4 The experimental protocol shown in.

[0149] Evaluation of the effect of coketone administra...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a pharmaceutical composition which includes a biocompatible polymer and a eukaryotic cell to be used as a drug for the prevention and/or treatment of tissue lesions ofthe central nervous system caused by cerebral vascular ischaemia. The present invention also relates to a pharmaceutical kit which includes a biocompatible polymer and a eukaryotic cell for the prevention and/or treatment of tissue lesions of the central nervous system caused by cerebral vascular ischaemia. The present invention can be used in particular in the human and veterinary pharmaceuticalfields.

Description

technical field [0001] The present invention relates to the use of the pharmaceutical composition as a medicament for preventing and / or treating tissue lesions of the central nervous system caused by cerebrovascular ischemia. [0002] The present invention also relates to a pharmaceutical kit for preventing and / or treating tissue lesions of the central nervous system caused by cerebrovascular ischemia. [0003] The invention can find particular application in the field of human and veterinary medicine. [0004] In the following description, references in parentheses refer to the list of references provided at the end of the text. Background technique [0005] Stroke (CVA) remains the leading cause of morbidity and the third leading cause of death in humans in industrialized countries. This pathological condition still takes a heavy toll: 10% to 12% of all deaths after the age of 65, with physical, cognitive or psychological sequelae in more than half of patients. Accordin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K35/12A61K35/28A61K35/15A61K35/35A61K31/737A61P9/10A61P25/00
CPCA61K9/0019A61K31/737A61K35/12A61K35/15A61K35/28A61K35/35A61K2300/00A61P25/00A61K31/721A61P9/10
Inventor 丹尼斯·巴里托米里亚姆·贝尔诺丹奥马尔·图扎尼杰尔姆·图坦马里-索菲·基泰
Owner 生物组织再生和修复公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap